---
title: "Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299753733.md"
description: "Edgewise Therapeutics detailed the preclinical profile of EDG-7500, a first-in-class cardiac sarcomere modulator for hypertrophic cardiomyopathy. Preclinical data showed improved cardiac relaxation without compromising pumping performance. Early clinical observations in patients were consistent with these findings. The company plans to discuss these results in an investor webcast today."
datetime: "2026-09-22T11:01:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299753733.md)
  - [en](https://longbridge.com/en/news/299753733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299753733.md)
generator: "portal-rs"
---

# Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathy

-   Edgewise Therapeutics outlined the preclinical profile for EDG-7500, a first-in-class cardiac sarcomere modulator for symptomatic hypertrophic cardiomyopathy. \* Results have already been generated in preclinical models; a peer-reviewed paper detailing the mechanism is scheduled for release later today. \* Data indicate improved cardiac relaxation while preserving overall pumping performance, supporting a diastolic-focused approach without apparent functional trade-offs. \* Early clinical observations in symptomatic hypertrophic cardiomyopathy patients were described as consistent with the preclinical findings. \* Management is set to discuss the findings in an investor webcast today at 8:30 a.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53384) on September 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EWTX.US](https://longbridge.com/en/quote/EWTX.US.md)

## Related News & Research

- [Edgewise Therapeutics doses first patient in Phase 2 EDG-15400 HFpEF trial](https://longbridge.com/en/news/301272560.md)
- [EWTX: EDG-7500 shows promise for HCM, preserving systolic function and improving diastolic relaxation](https://longbridge.com/en/news/299770577.md)
- [AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study](https://longbridge.com/en/news/302992595.md)
- [Amazon.com, Inc. $AMZN Stock Sold by Cohen Klingenstein LLC](https://longbridge.com/en/news/302980467.md)
- [Xencor Reports 45.5% Confirmed Response Rate for XmAb819 at Selected Dose in Phase 1 Kidney Cancer Trial](https://longbridge.com/en/news/302982565.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**